A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

2023-506156-25-00 Protocol CSET N°2020/3138 Phase I and Phase II (Integrated) - Other Ended

Start 13 Nov 2020 · End 13 Jan 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol CSET N°2020/3138

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 30
Countries 1
Sites 2

Advanced hepatocellular carcinoma

Key facts

Sponsor
Institut Gustave Roussy, Institut Gustave Roussy
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Nov 2020 → 13 Jan 2025
Decision date (initial)
2024-11-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-506156-25-00
EudraCT number
2020-003766-40

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced hepatocellular carcinoma

VersionLevelCodeTermSystem organ class
20.0 PT 10073071 Hepatocellular carcinoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Gustave Roussy

Sponsor organisation
Institut Gustave Roussy
Address
114 Rue Edouard Vaillant
City
Villejuif
Postcode
94800
Country
France

Scientific contact point

Organisation
Institut Gustave Roussy
Contact name
Regulatory Team

Public contact point

Organisation
Institut Gustave Roussy
Contact name
Regulatory Team

Institut Gustave Roussy

Sponsor organisation
Institut Gustave Roussy
Address
114 Rue Edouard Vaillant
City
Villejuif
Postcode
94800
Country
France

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 30 2
Rest of world 0

Investigational sites

France

2 sites · Ended
Service Hospitalier Frédéric Joliot - Commissariat à Energie Atomique
ONCOLOGY, 114, rue Édouard-Vaillant, Villejuif
Gustave Roussy
ONCOLOGY, 114, rue Édouard-Vaillant, Villejuif

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2020-11-13 2025-01-13 2020-11-13 2024-09-13

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-26 France Acceptable
2024-11-08
2024-11-08